These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 22884159)

  • 1. Multi-targeted tyrosine kinase inhibitor sunitinib: a novel strategy for sporadic malignant pheochromocytoma.
    Sun FK; He HC; Su TW; Zhou WL; Huang X; Dai J; Shen ZJ
    Chin Med J (Engl); 2012 Jun; 125(12):2231-4. PubMed ID: 22884159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors.
    Jimenez C; Cabanillas ME; Santarpia L; Jonasch E; Kyle KL; Lano EA; Matin SF; Nunez RF; Perrier ND; Phan A; Rich TA; Shah B; Williams MD; Waguespack SG
    J Clin Endocrinol Metab; 2009 Feb; 94(2):386-91. PubMed ID: 19017755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sunitinib, a novel therapy for anthracycline- and cisplatin-refractory malignant pheochromocytoma.
    Park KS; Lee JL; Ahn H; Koh JM; Park I; Choi JS; Kim YR; Park TS; Ahn JH; Lee DH; Kim TW; Lee JS
    Jpn J Clin Oncol; 2009 May; 39(5):327-31. PubMed ID: 19264767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma.
    Joshua AM; Ezzat S; Asa SL; Evans A; Broom R; Freeman M; Knox JJ
    J Clin Endocrinol Metab; 2009 Jan; 94(1):5-9. PubMed ID: 19001511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Antiangiogenic therapy of malignant pheochromocytoma and paraganglioma with the view to the recent scientific developments].
    Kukla U; Łabuzek K; Chronowska J; Bobrzyk M; Madej P; Okopień B
    Pol Merkur Lekarski; 2015 Apr; 38(226):191-5. PubMed ID: 25938384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Both sunitinib and sorafenib are effective treatments for pheochromocytoma in a xenograft model.
    Denorme M; Yon L; Roux C; Gonzalez BJ; Baudin E; Anouar Y; Dubessy C
    Cancer Lett; 2014 Oct; 352(2):236-44. PubMed ID: 25016061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sunitinib treatment for refractory malignant pheochromocytoma.
    Nemoto K; Miura T; Shioji G; Tsuboi N
    Neuro Endocrinol Lett; 2012; 33(3):260-4. PubMed ID: 22635080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas.
    Ayala-Ramirez M; Chougnet CN; Habra MA; Palmer JL; Leboulleux S; Cabanillas ME; Caramella C; Anderson P; Al Ghuzlan A; Waguespack SG; Deandreis D; Baudin E; Jimenez C
    J Clin Endocrinol Metab; 2012 Nov; 97(11):4040-50. PubMed ID: 22965939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sunitinib for refractory malignant pheochromocytoma: two case reports.
    Hata J; Haga N; Ishibashi K; Takahashi N; Ogawa S; Kataoka M; Akaihata H; Satoh Y; Koguchi T; Kojima Y
    Int Urol Nephrol; 2014 Jul; 46(7):1309-12. PubMed ID: 24510251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three cases of sporadic medullary thyroid carcinoma in progression treated with sunitinib.
    Currás Freixes M; Díaz Pérez JÁ; Casado Herráez A; Ochagavía Cámara S
    Endocrinol Nutr; 2014 Jan; 61(1):62-3. PubMed ID: 24125629
    [No Abstract]   [Full Text] [Related]  

  • 11. A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial.
    O'Kane GM; Ezzat S; Joshua AM; Bourdeau I; Leibowitz-Amit R; Olney HJ; Krzyzanowska M; Reuther D; Chin S; Wang L; Brooks K; Hansen AR; Asa SL; Knox JJ
    Br J Cancer; 2019 Jun; 120(12):1113-1119. PubMed ID: 31105270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sunitinib in patients with metastatic renal cell carcinoma.
    Motzer RJ; Rini BI; Bukowski RM; Curti BD; George DJ; Hudes GR; Redman BG; Margolin KA; Merchan JR; Wilding G; Ginsberg MS; Bacik J; Kim ST; Baum CM; Michaelson MD
    JAMA; 2006 Jun; 295(21):2516-24. PubMed ID: 16757724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term response and postsurgical complete remissions after treatment with sunitinib malate, an oral multitargeted receptor tyrosine kinase inhibitor, in patients with metastatic renal cell carcinoma.
    Ayllon J; Beuselinck B; Morel A; Barrascout E; Medioni J; Scotte F; Oudard S
    Cancer Invest; 2011 May; 29(4):282-5. PubMed ID: 21469976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvement in hereditary hemorrhagic telangiectasia after treatment with the multi-kinase inhibitor Sunitinib.
    Droege F; Thangavelu K; Lang S; Geisthoff U
    Ann Hematol; 2016 Dec; 95(12):2077-2078. PubMed ID: 27525726
    [No Abstract]   [Full Text] [Related]  

  • 15. Tyrosine kinase inhibitors in treatment of fibrous histiocytoma.
    Mauri D; Panou C; Valachis A; Kamposioras K; Tsali L
    Exp Oncol; 2009 Mar; 31(1):60-1. PubMed ID: 19300420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.
    Raymond E; Dahan L; Raoul JL; Bang YJ; Borbath I; Lombard-Bohas C; Valle J; Metrakos P; Smith D; Vinik A; Chen JS; Hörsch D; Hammel P; Wiedenmann B; Van Cutsem E; Patyna S; Lu DR; Blanckmeister C; Chao R; Ruszniewski P
    N Engl J Med; 2011 Feb; 364(6):501-13. PubMed ID: 21306237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The oral tyrosine kinase inhibitors lapatinib and sunitinib: new opportunities for the treatment of brain metastases from breast cancer?
    Addeo R; Caraglia M
    Expert Rev Anticancer Ther; 2011 Feb; 11(2):139-42. PubMed ID: 21342029
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice.
    Agostino NM; Chinchilli VM; Lynch CJ; Koszyk-Szewczyk A; Gingrich R; Sivik J; Drabick JJ
    J Oncol Pharm Pract; 2011 Sep; 17(3):197-202. PubMed ID: 20685771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of response in malignant tumors treated with the multitargeted tyrosine kinase inhibitor sorafenib: a multitechnique imaging assessment.
    Maksimovic O; Schraml C; Hartmann JT; Bitzer M; Claussen CD; Pintoffl J; Horger M
    AJR Am J Roentgenol; 2010 Jan; 194(1):5-14. PubMed ID: 20028898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined positron emission tomography/computed tomography in sunitinib therapy assessment of patients with metastatic renal cell carcinoma.
    Revheim ME; Winge-Main AK; Hagen G; Fjeld JG; Fosså SD; Lilleby W
    Clin Oncol (R Coll Radiol); 2011 Jun; 23(5):339-43. PubMed ID: 21134733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.